PRMT5 and non-small cell lung carcinoma: Variable sensitivity to PRMT5 inhibitors was observed in 22 MTAP-deleted NSCLC cell lines (9 <i>EGFR</i>-mutant, 7 <i>KRAS</i>-mutant, 6 <i>ALK</i>-rearranged), with responses seen in TKI-sensitive and TKI-resistant lines.